Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Lotiglipron

Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity

Pfizer · Phase 2 · Terminated · Enrollment 902

NCT05579977

EudraCT 2022-002834-15

ArmNauseaVomitingDiarrheaDiscontinuationDeaths
PF-07081532 20 mg T2DMn/rn/rn/rn/rn/r
PF-07081532 40 mg T2DMn/rn/rn/rn/rn/r
PF-07081532 80 mg T2DMn/rn/rn/rn/rn/r
PF-07081532 160 mg T2DMn/rn/rn/rn/rn/r
PF-07081532 260 mg T2DMn/rn/rn/rn/rn/r
Placebo T2DMn/rn/rn/rn/rn/r
PF-07081532 80 mg Obesityn/rn/rn/rn/rn/r
PF-07081532 140 mg Obesityn/rn/rn/rn/rn/r
PF-07081532 200 mg Obesity (Option 1)n/rn/rn/rn/rn/r
PF-07081532 200 mg Obesity (Option 2)n/rn/rn/rn/rn/r
PF-07081532 260 mg Obesityn/rn/rn/rn/rn/r
Rybelsus 14 mg T2DMn/rn/rn/rn/rn/r
Placebo Obesityn/rn/rn/rn/rn/r

A count stays a count. This page does not turn a count into a percent.